Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
JNJ-95475939 in Dermatitis, Atopic: NCT06881251 Clinical Landscape Report 2026
16 October 2026
NCT06881251 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carfilzomib in Multiple Myeloma: NCT06879379 Clinical Landscape Report 2026
16 October 2026
NCT06879379 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab Biosimilar (Qilu Pharmaceutical) in Dermatitis, Atopic: NCT06884891 Clinical Landscape Report 2026
16 October 2026
NCT06884891 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Icotrokinra Hydrochloride in Arthritis, Psoriatic: NCT06878404 Clinical Landscape Report 2026
16 October 2026
NCT06878404 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
METR-NK Cells(Anhui Provincial Cancer Hospital) in Ovarian Epithelial Carcinoma: NCT06884345 Clinical Landscape Report 2026
16 October 2026
NCT06884345 clinical landscape for Ovarian Epithelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Alloreactive NK Cells(IRCCS Azienda Ospedaliero-Universitaria di Bologna) in Acute Myeloid Leukemia: NCT06885476 Clinical Landscape Report 2026
16 October 2026
NCT06885476 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
COM-701 in Platinum-sensitive epithelial ovarian cancer: NCT06888921 Clinical Landscape Report 2026
16 October 2026
NCT06888921 clinical landscape for Platinum-sensitive epithelial ovarian cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Lenalidomide in Multiple Myeloma: NCT06892522 Clinical Landscape Report 2026
16 October 2026
NCT06892522 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bimekizumab in Plaque psoriasis: NCT06888193 Clinical Landscape Report 2026
16 October 2026
NCT06888193 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Niraparib Tosylate in Ovarian Epithelial Carcinoma: NCT06887933 Clinical Landscape Report 2026
16 October 2026
NCT06887933 clinical landscape for Ovarian Epithelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LCAR-M61SQ Cell(First Affiliated Hospital of Wenzhou Medical University) in Multiple Myeloma: NCT06888752 Clinical Landscape Report 2026
16 October 2026
NCT06888752 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Foralumab in Multiple Sclerosis, Secondary Progressive: NCT06890923 Clinical Landscape Report 2026
16 October 2026
NCT06890923 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…